Podcasts

John RP Tesser, MD, rheumatology specialist, Arizona Arthritis & Rheumatology Associates, and clinical adjunct professor, Midwestern University College of Health Sciences, discusses the MIRROR trial, a study which showed the addition of an...

Craig Gravina, chief technology officer, ObvioHealth, sheds some light on the current digital therapeutics landscape, including regulatory challenges, the prescription DTx model, and solutions to improve clinical trial research.

Gary Owens, MD, discusses how payers might develop formularies for prescription digital therapeutics, as well as what metrics may be used to determine their efficacy.

Gary Owens, MD, president, Gary Owens Associates, discusses the ALPINE study and predicts how zanubrutinib's recently approved indication for chronic lymphocytic leukemia will transform the standard of care.

Chuck Thigpen, PhD, PT, ATC, clinical research scientist, ATI Physical Therapy, reviews the updated guidance on pain management from the Centers for Disease Control and Prevention, as well as how patients and payers typically cover the costs...

Adam Kittai, MD, hematology specialist and assistant professor of medicine, Ohio State University; Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center; and Jeffrey Dunn, PharmD, MBA, chief clinical officer,...

Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center, offers insight into how a new second-generation BTK inhibitor might impact the treatment paradigm in chronic lymphocytic leukemia.

Jeffrey Dunn, PharmD, MBA, chief clinical officer, Cooperative Benefits Group, discusses the rationale driving coverage for new and existing drugs and shares how US stakeholders account for metrics like quality of life.

Alan Vernon, vice president of health care solutions, CQ Fluency, reviews how many people in the United States do not speak English as their primary language and offers advice for payers and providers to keep patients engaged in their care.

Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.